Novo Nordisk A/S (NONOF)
OTC Markets OTCPK: NONOF
· Real-Time Price · USD
43.36
-3.84 (-8.14%)
At close: Aug 12, 2026, 9:31 AM
Novo Nordisk A/S (NONOF) Stock Price, Analysis & Data
-8.14% (1D)
| Bid | 44 |
| Market Cap | 189.97B |
| Revenue (ttm) | 329.43B |
| Net Income (ttm) | 116.44B |
| Beta | 0.35 |
| EPS (ttm) | 4.06 |
| PE Ratio (ttm) | 10.68 |
| Forward PE | n/a |
| P/B (ttm) | 5.61 |
| P/S (ttm) | 0.58 |
| Earnings Date | Nov 4, 2026 |
| Ask | 46.71 |
| Volume | 100 |
| Avg. Volume (20D) | 40,785 |
| Open | 43.36 |
| Previous Close | 47.20 |
| Day's Range | 43.36 - 43.36 |
| 52-Week Range | 34.00 - 64.75 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $1.8 (3.83%) |
| Ex-Dividend Date | Aug 14, 2026 |
About NONOF
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Feb 22, 2010
Employees 66,700
Stock Exchange OTC Markets OTCPK
Ticker Symbol NONOF
Website https://www.novonordisk.com
Financial Performance
In 2025, Novo Nordisk A/S's revenue was 309.06B, an increase of 6.43% compared to the previous year's 290.4B. Earnings were 102.43B, an increase of 1.43%.
Financial StatementsNovo Nordisk A/S is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2